Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321726 | 0.81 | KDM4E (0.69) | POLBKDM4ERAB9AKMT2ATDP1 | |
| SCHEMBL1927756 | 0.81 | POLB (0.56) | POLBKDM4ERAB9AKMT2ATDP1 | |
| SCHEMBL1928614 | 0.78 | KDM4E (0.67) | POLBKDM4ERAB9AKMT2ATDP1 | |
| SCHEMBL3405632 | 0.78 | KDM4E (0.86) | POLBKDM4ERAB9AKMT2ATDP1 | |
| SCHEMBL10798879 | 0.75 | HTR7 (0.67) | KDM4ERAB9AKMT2ATDP1ALDH1A1 | |
| SCHEMBL1929728 | 0.75 | POLB (0.56) | POLBKDM4ERAB9AKMT2ATDP1 | |
| SCHEMBL1928194 | 0.75 | KDM4E (0.64) | POLBKDM4ERAB9AKMT2ATDP1 | |
| SCHEMBL2344935 | 0.73 | HTR7 (0.64) | KDM4ERAB9AKMT2ATDP1ALDH1A1 | |
| SCHEMBL701534 | 0.73 | HTR7 (0.64) | KDM4ERAB9AKMT2ATDP1ALDH1A1 | |
| SCHEMBL1927874 | 0.73 | POLB (0.51) | POLBKDM4ERAB9AKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | MORLEY ANDREW DAVID | 2009-08-27 | — | — | US | disclosed |
| US-7553868-B2 | Thiophene carboxamides as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-06-30 | — | — | US | disclosed |
| EP-1583756-B9 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1583756-B1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-05-25 | — | — | US | disclosed |
| EP-1583756-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063185-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | RELA, NFKBIA, CSNK1E | POLB 1226/4885KDM4E 343/4885RAB9A 4041/4885 |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | RELA, NFKBIA, CHUK | POLB 1421/4885KDM4E 550/4885RAB9A 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.